Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2/3, Prospective, Randomized, Multi-center, Open-Label, Controlled Trial to Assess the Efficacy and Safety of Cellular Immunotherapy With MDR-102 for Induction of Immune Quiescence™in Recipients of HLA-mismatched, Living Donor Kidney Transplants

Trial Profile

A Phase 2/3, Prospective, Randomized, Multi-center, Open-Label, Controlled Trial to Assess the Efficacy and Safety of Cellular Immunotherapy With MDR-102 for Induction of Immune Quiescence™in Recipients of HLA-mismatched, Living Donor Kidney Transplants

Not yet recruiting
Phase of Trial: Phase II/III

Latest Information Update: 22 Jan 2019

At a glance

  • Drugs MDR 102 (Primary)
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Sponsors Medeor Therapeutics
  • Most Recent Events

    • 11 Jan 2019 Planned initiation date changed from 1 Dec 2018 to 1 Mar 2019.
    • 26 Jul 2018 Status changed from planning to not yet recruiting.
    • 30 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top